MOUNTAIN VIEW, Calif. — October 7, 2026

RenovoRx announced that the first patient has been enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont (UVM) evaluating its Trans-Arterial Micro-Perfusion (TAMP™) platform in borderline resectable pancreatic ductal adenocarcinoma (PDAC). The study, titled “PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP,” is evaluating chemotherapy delivered through RenovoRx’s FDA-cleared RenovoCath® device before surgical resection. A second patient was also progressing toward TAMP treatment one week after trial initiation. PRISM-TAMP represents the first RenovoRx-supported investigator-initiated trial to advance to patient enrollment and expands clinical evaluation of TAMP into a treatment setting beyond the company’s ongoing program in locally advanced pancreatic cancer.

PRISM-TAMP Evaluates Neoadjuvant Targeted Chemotherapy

PRISM-TAMP is designed to evaluate gemcitabine delivered through the TAMP platform as a neoadjuvant treatment before surgery in patients with borderline resectable PDAC. UVM plans to enroll approximately 10 patients in the study, which is registered on ClinicalTrials.gov as NCT07477418. The primary objectives are to assess tumor regression, intraoperative surgical margins and overall safety and tolerability following pre-surgical treatment. Borderline resectable pancreatic tumors can involve nearby blood vessels, making complete surgical removal more challenging. Standard treatment commonly involves chemotherapy, with or without radiation, before surgery, whereas TAMP is designed to deliver therapy locally near the tumor through the arterial system.

TAMP Expands Targeted Drug Delivery Strategy

The PRISM-TAMP study is evaluating an intra-arterial gemcitabine drug-device combination using RenovoCath, which enables RenovoRx’s targeted TAMP approach. The platform is designed to deliver therapeutic agents across the arterial wall near a tumor site, potentially providing localized exposure while reducing reliance on systemic intravenous delivery. RenovoCath is an FDA-cleared device intended for isolation of blood flow and delivery of fluids, including diagnostic and therapeutic agents, to selected sites in the peripheral vascular system. It is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion and chemotherapeutic drug infusion. The intra-arterial gemcitabine combination, however, remains investigational and has not been approved for commercial sale.

Advertisement

cGxPJobs Banner

RenovoRx Continues Phase 3 TIGeR-PaC Program

The new investigator-initiated study comes as RenovoRx continues its pivotal Phase 3 TIGeR-PaC trial, which is evaluating intra-arterial gemcitabine delivered through RenovoCath in locally advanced pancreatic cancer. RenovoRx completed enrollment in TIGeR-PaC in August 2026, with trial completion expected in the first half of 2027 and topline results anticipated in the second half of 2027. The company said capital-efficient investigator-initiated trials such as PRISM-TAMP allow independent investigators to explore additional applications for TAMP while RenovoRx remains focused on its pivotal program. The company is also expanding commercialization of RenovoCath as a standalone device and reported approximately $1.1 million in 2025 sales, followed by record quarterly revenue of $909,000 in the second quarter of 2026.

Source::RenovoRx, press release